Resmetirom Eases Worry in Cirrhosis Patients
A post hoc analysis of the MAESTRO-NAFLD-1 trial links the MASH drug to better mental health outcomes in compensated cirrhosis.
Updated on Nov. 7, 2026 in Diabetes
A post hoc analysis of the phase 3 MAESTRO-NAFLD-1 trial found that 52 weeks of resmetirom 80 mg was associated with improved Worry scores among 160 patients with compensated MASH cirrhosis. Health distress also showed a trend toward improvement.
Why it matters
Cirrhosis from metabolic liver disease carries a heavy burden beyond physical damage, and quality of life measures help capture that toll. The findings suggest that treatment may benefit how patients feel day to day, not only their liver tests.
Among 160 patients with compensated MASH cirrhosis, the CLDQ-MASH Worry domain improved by a mean of +0.30 (P = .001) after 52 weeks of resmetirom 80 mg. Patients with at least a 25% relative drop in liver stiffness also reported better bleeding gums and joint pain.
The players
MAESTRO-NAFLD-1
A phase 3 52-week safety trial of resmetirom that included an open-label cohort of patients with compensated MASH cirrhosis.
Resmetirom
An oral thyroid hormone receptor-beta agonist approved by the US FDA for adults with noncirrhotic MASH and moderate to advanced fibrosis.
The details
The analysis of MAESTRO-NAFLD-1 used LDQoL, CLDQ-MASH, CLDQ-MASH Symptom Questionnaire, and WPAI instruments to track quality of life. Baseline impairment was greatest in sleep and fatigue domains, and the investigators reported that quality of life may improve further if treatment continues and fibrosis keeps improving.
Timeline
November 5, 2026: Analysis presented at The Liver Meeting 2026 in Denver, Colorado.
November 5-9, 2026: The Liver Meeting 2026 takes place.
Health Landscape
The FDA approved resmetirom for adults with noncirrhotic MASH and moderate to advanced fibrosis, leaving the cirrhotic population outside that label. This analysis adds quality-of-life evidence from patients with compensated MASH cirrhosis, a group the approval did not cover.
Patients with compensated MASH cirrhosis may experience fewer worries and less health distress with treatment, though these results come from a post hoc analysis. Patients should discuss how any therapy might fit their own liver condition with their clinicians.
The takeaway
Quality of life is an important outcome in liver disease, not just lab values or fibrosis scores. Patients concerned about how their cirrhosis affects daily life can ask their care team whether their symptoms and mental health are being tracked.
Further reading
Explore more on Diabetes to see how metabolic liver disease connects with broader metabolic health.
